BridgeBio Pharma, Inc. Common Stock (BBIO) is a publicly traded Healthcare sector company. As of October 3, 2026, BBIO trades at $66.72 with a market cap of $13.15B and a P/E ratio of -18.74. BBIO moved +0.48% today. Year to date, BBIO is -14.04%; over the trailing twelve months it is +26.22%. Its 52-week range spans $28.33 to $93.42. Analyst consensus is strong buy with an average price target of $111.44. Rallies surfaces BBIO's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks BBIO insider trades, Form 4 activity, executive purchases, executive sales, shares, prices, and transaction dates when available.
| Metric | Value |
|---|---|
| Price | $66.72 |
| Market Cap | $13.15B |
| P/E Ratio | -18.74 |
| EPS | $-3.56 |
| Dividend Yield | 0.00% |
| 52-Week High | $93.42 |
| 52-Week Low | $28.33 |
| Volume | 2.29M |
| Avg Volume | 0 |
| Revenue (TTM) | $713.07M |
| Net Income | $-702.02M |
| Gross Margin | 94.44% |
17 analysts cover BBIO: 0 strong buy, 16 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $111.44.